Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients

Multiple Sclerosis

Volumn 11, Issue 3, 2005, Pages 272-275

  Sfagos, Constantinos ^a   Makis, Alexandros C ^b,c   Chaidos, Aristeidis ^b   Hatzimichael, Eleftheria C ^b   Dalamaga, Androniki ^a   Kosma, Katerina ^a   Bourantas, Konstantinos L ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c NONE   (Greece)

Author keywords

Ferritin; Iron; Multiple sclerosis; Transferrin; Transferrin receptor

Indexed keywords

FERRITIN; IRON; MYELIN; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ADULT; ANAMNESIS; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; IRON METABOLISM; MALE; MEDICAL EXAMINATION; MULTIPLE SCLEROSIS; MYELINATION; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PROTEIN BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; FEMALE; FERRITINS; HUMANS; IRON; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OXIDATIVE STRESS; RECEPTORS, TRANSFERRIN; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TRANSFERRIN;

EID: 20144368039     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1171oa     Document Type: Article

References (27)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Toshdiwal PK, Zarling EJ. Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem Res 1992; 17: 205-207.
3. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997; 760: 298-303.
4. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92.
5. Valberg LS, Flanagan PR, Kertesz A, Ebers GC. Abnormalities in iron metabolism in multiple sclerosis. Can J Neurol Sci 1989; 16: 184-86.
6. Kotze MJ, de Villiers JN, Rooney RN, Grobbelaar JJ, Mansvelt EP, Bouwens CS et al. Analysis of the NRAMP1 gene implicated in iron transport: association with multiple sclerosis and age effects. Blood Cells Mol Dis 2001; 27: 44-53.
7. LeVine SM, Lynch SG, Ou CN, Wulser MJ, Tam E, Boo N. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res 1999; 821: 511-15.
8. Zeman D, Adam P, Kalistova H, Sobek O, Kelbich P, Andel J et al. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients. Acta Neurol Scand 2000; 101: 89-94.
9. Huebers HA, Finch CA. The physiology of transferrin and transferrin receptor. Physiol Rev 1987; 67: 520-82.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
11. Aisen P. Iron metabolism in health and disease. In Brock JH, Halliday JW, Pippard MJ, Powell LW eds. Iron metabolism: an evolutionary perspective, London: Saunders, 1994: 1-30.
12. Roskams AJI, Connor JR. Iron, transferrin, and ferritin in the rat brain during development and aging. J Neurochem 1994; 63: 709-16.
13. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31; 1111-37.
14. Grant SM, Wiesinger JA, Beard JL, Cantorna MT. Iron-deficient mice fail to develop autoimmune encephalomyelitis. J Nutr 2003; 133: 2635-38.
15. Lynch SG, Peters K, LeVine SM. Desforrioxamine in chronic progressive multiple sclerosis: a pilot study. Mult Scler 1996; 2: 157-60.
16. Lynch SG, Fonseca T, Levine SM. A multiple course trial of desforrioxamine in chronic progressive multiple sclerosis. Cell Mol Biol (Noisy-le-grand) 2000; 46: 865-69.
17. Vladimirova O, O'Connor J, Cahill A, Alder H, Butunoi C, Kalman B. Oxidative damage to DNA in plaques of MS brains. Mult Scler 1998; 4: 413-18.
18. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
19. LeVine SM, Maiti S, Emerson MR, Pedchenko TV. Apoferritin attenuates experimental allergic encephalomyelitis in SJL mice. Dev Neurosci 2002; 24: 177-83.
20. Del Principe D, Menichelli A, Colistra C. The ceruloplasmin and transferrin system in cerebrospinal fluid of acute leukemia patients. Acta Paediatr Scand 1989; 78: 327-28.
21. Gutteridge JM. Iron and oxygen: a biologically damaging mixture. Acta Paediatr Scand (Suppl) 1989; 361: 78-85.
22. Lum JB, Infante AJ, Makker DM, Yang F, Bowman BH. Transferrin synthesis by inducer T lymphocytes. J Clin Invest 1986; 77: 841-49.
23. Hulet SW, Heyliger SO, Powers S, Connor JR. Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J Neurosci Res 2000; 61: 52-60.
24. Hulet SW, Powers S, Connor JR. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J Neurol Sci 1999; 165: 48-55.
25. Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol 2000; 20: 77-95.
26. Woith W, Nusslein I, Antoni C, Dejica DI, Winkler TH, Herrmann M et al. A soluble form of the human transferrin receptor is released by activated lymphocytes in vitro. Clin Exp Immunol 1993; 92: 537-42.
27. Mehindate K, Sahlas DJ, Frankel D, Mawal Y, Liberman A, Corcos J et al. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem 2001; 77: 1386-95.